The short answer
Weghuber and colleagues published STEP TEENS in the New England Journal of Medicine in December 2022. Among 201 randomised adolescents, mean BMI change at week 68 was −16.1% with semaglutide against +0.6% with placebo, an estimated difference of −16.7 percentage points.
Key facts
- Published
- NEJM, 15 December 2022 (PMID 36322838)
- Randomised
- 201
- Completed treatment
- 180 (90%)
- Duration
- 68 weeks
- Mean BMI change
- −16.1% vs +0.6% placebo
- Estimated difference
- −16.7 points (95% CI −20.3 to −13.2)
- ≥5% weight loss
- 73% vs 18% (OR 14.0)
- GI adverse events
- 62% vs 42%
What the trial established
That a GLP-1 receptor agonist produces substantial BMI reduction in adolescents with obesity over 68 weeks. The primary result (−16.1% against +0.6%) is a large separation, and the confidence interval on the difference runs from −20.3 to −13.2 percentage points, which is a precise as well as a large effect.
The completion rate is part of the result
180 of 201 participants, 90%, completed treatment. That is high for a 68-week trial in any population and unusually so in adolescents, who are generally harder to retain. A high completion rate narrows the gap between what the efficacy and treatment-policy estimands would show, which makes the headline figure more robust than it would otherwise be.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The secondary endpoint that gets quoted most
73% of participants on semaglutide, 95 of 131, achieved weight loss of 5% or more, against 18% on placebo, 11 of 62. The odds ratio is 14.0 with a confidence interval from 6.3 to 31.0. That is the figure most often repeated, and it is a secondary endpoint measured in weight rather than the BMI primary.
The safety finding that rarely gets repeated
Cholelithiasis (gallstones) occurred in 5 participants, 4%, in the semaglutide group and in none on placebo. Rapid weight reduction is an established risk factor for gallstone formation, so this is mechanistically expected rather than surprising, and it belongs beside the efficacy numbers rather than in a footnote.
The rest of the safety picture
Gastrointestinal adverse events occurred in 62% on semaglutide against 42% on placebo, a substantial excess and consistent with the drug class throughout. Serious adverse events were reported in 11% of the semaglutide group and 9% of placebo, which is a much smaller difference than the gastrointestinal figures suggest.
What the trial does not settle
What happens after 68 weeks, in a population who may be treated for decades. Long-term data in adolescents does not exist for any compound in this class, and the questions about growth, puberty and duration of exposure are open because the trials that would answer them have not been run.
The necessary boundary
Semaglutide is a licensed medicine, and STEP TEENS was a registered trial conducted under clinical supervision with ethics approval and specialist paediatric oversight. Nothing supplied on this site is semaglutide, is related to it, or is appropriate for any person, least of all a child.
Frequently asked questions
What did STEP TEENS find?
Mean BMI change at 68 weeks of −16.1% with semaglutide against +0.6% with placebo among 201 randomised adolescents.
Were there safety findings?
Gastrointestinal adverse events in 62% versus 42%, and cholelithiasis in 5 participants (4%) on semaglutide with none on placebo.
Is there long-term data?
No. The trial ran 68 weeks, and long-term adolescent data does not exist for any compound in this class.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedWeghuber D et al., Once-Weekly Semaglutide in Adolescents with Obesity. NEJM 2022 (PMID 36322838)pubmed.ncbi.nlm.nih.gov
- PubMedKotecha P et al., Efficacy and Safety of GLP-1 RAs in Children and Adolescents. JAMA Pediatr 2025 (PMID 40952752)pubmed.ncbi.nlm.nih.gov
- PubMedSedenho-Prado LG et al., Metabolic outcomes and safety of GLP-1 receptor agonists in children and adolescents. Int J Obes 2025 (PMID 40269110)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- What Is Actually Registered, and at What PhaseA Phase 3 in 160 adolescents aged 12-17, and a Phase 1 safety study in 28 children aged 6-11. The distinction matters for what results will mean.
- When Low Muscle and High Fat Occur TogetherA 2026 paper describes sarcopenic obesity in children using clinical data and a juvenile mouse model. Why the body composition question is sharper in the young.
- Slowing the Stomach Changes When a Tablet ArrivesMost oral drugs are absorbed in the small intestine, so gastric emptying controls when absorption starts. Slowing it flattens the concentration peak.
- One Compound, Not the Whole ClassTirzepatide reduced peak contraceptive hormone concentrations by 55-66% in reported data. Semaglutide, liraglutide and dulaglutide did not show the effect.
- Where the Thyroid Warning Came FromRodents given GLP-1 agonists developed C-cell hyperplasia and tumours. The 2010 paper that established it, and why it was an on-target effect.